WeVote
Log In

Bill

Bill

H 522

An act relating to prescriptions for psychotropic medications used by children and youth in the Dr. Dynasaur program

2025-2026 Regular Session Introduced by Daisy Berbeco

Vermont H.522 would standardize, monitor, and coordinate prescribing of psychotropic meds for Dr. Dynasaur youths to improve safety and treatment quality.

Read first time and referred to the Committee on Health Care
0
WeVote Research Nonpartisan
Bill Summary · H 522

Overview

House Bill H. 522 (2025-2026, Vermont) aims to regulate prescriptions for psychotropic medications used by children and youth enrolled in the Dr. Dynasaur program. The act focuses on ensuring appropriate prescribing practices, monitoring, and potential safeguards to support the mental health treatment of young Vermonters within the state’s public health coverage program.

Purpose and intent

  • Improve oversight of psychotropic medication use among children and adolescents in Dr. Dynasaur.
  • Promote safer, more effective treatment through standardized prescribing practices.
  • Enhance coordination between prescribers, families, and the public health system to support youth mental health care.

Key provisions and changes (as proposed)

  • Target population: Children and youth who are covered by the Dr. Dynasaur program and are prescribed psychotropic medications.
  • Prescribing standards: Establish or reinforce guidelines for clinicians prescribing psychotropic drugs to minors, with emphasis on appropriate indications, dosing considerations, and monitoring.
  • Monitoring and follow-up: Require ongoing evaluation of medication effectiveness and adverse effects, potentially including recommended intervals for follow-up visits, assessment tools, or check-ins.
  • Care coordination: Encourage communication among prescribers, pediatricians/primary care providers, mental health professionals, families, and the Dr. Dynasaur program to coordinate care.
  • Safety and risk management: May include requirements related to informed consent, disclosure of potential risks, and consideration of non-pharmacological interventions when appropriate.
  • Data and reporting: Possible provisions for record-keeping, monitoring outcomes, and reporting to state health authorities or program administrators to track utilization and safety signals.
  • Exceptions and flexibility: Provisions for clinical judgment in complex cases, with processes for review or escalation if concerns arise about a patient’s safety or well-being.

Who/what would be affected

  • Pediatric patients and youth enrolled in the Dr. Dynasaur program who are prescribed psychotropic medications (e.g., antidepressants, stimulants, antipsychotics, anxiolytics, etc.).
  • Healthcare providers (pediatricians, child psychiatrists, family medicine physicians, and other prescribers) who treat minors in the program.
  • Dr. Dynasaur program administrators and case managers who oversee coverage and care coordination.
  • Families and caregivers of affected youths, who may experience enhanced guidance and requirements around monitoring and follow-up.

Procedural and timeline aspects

  • Status: Read first time and referred to the Committee on Health Care on January 6, 2026.
  • Next steps: The Health Care Committee would review, possibly amend, and vote on the bill before it could progress to the full House for debate and potential passage.
  • Implementation timeline: If enacted, provisions would likely specify an effective date and any phased rollout, along with guidance for providers and program administrators.

Potential impact

  • Improved safety and quality of care for minors receiving psychotropic medications under Dr. Dynasaur.
  • Greater consistency in prescribing practices and follow-up, potentially reducing adverse effects and medication trials without adequate monitoring.
  • Enhanced collaboration among families, clinicians, and program administrators to support appropriate treatment decisions.
  • Potential administrative burden on prescribers and program staff, balanced by clearer guidelines and monitoring requirements.

Note: This summary reflects the bill’s stated focus and typical components of similar legislation. For precise language, specific statutory changes, definitions, and enacted timelines, the bill’s text and any amendments from committee hearings should be consulted.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.